Chemical reagent intended exclusively for laboratory tests (Research Use Only). It is not a medicinal product, dietary supplement or food. It is not intended for use on humans or animals. Sales only to registered research units and laboratories.
S-23 is a non-steroidal selective androgen receptor modulator (SARM) from the arylpropionamide class, developed in the first decade of the 21st century by a team GTx Inc. (James T. Dalton, Amanda Jones and associates) as a candidate for hormonal male contraception. The team’s landmark study – Jones et al. 2009 (Endocrinology) – described in a rat model the ability of S-23 to reversibly inhibit spermatogenesis while maintaining the anabolic effect in muscle and bone, which distinguished this compound from previous arylpropionamide ligands tested by the same center (Andarine/S-4, bicalutamide).
In a chemical context, S-23 belongs to the family arylpropionamides — structural derivatives of the non-steroidal anti-androgen bicalutamide, from which Andarine (S-4) is also derived. Modifications of the halogen substituents in the S-23 molecule shift its pharmacological profile from partial agonism/antagonism (typical of earlier arylpropionamides) towards full, strong androgen receptor (AR) agonism with one of the highest affinities reported for this class (Ki in the order of single nanomoles).
This reagent is supplied in a 60 capsules of 10 mg S-23 — form adapted to chronic oral exposure protocols in in vivo models on rodents and to standardize the dose in long-term androgen studies. Purity verified by HPLC ≥98%, identity confirmed by mass spectrometry, COA available for each batch.
Regulatory status
S-23 has not completed any phase of human clinical trials – the entire evidence base comes from preclinical models (rat, mouse, cell cultures). No registration as a drug with the EMA, FDA or anywhere in the world. Not authorized by EFSA as an ingredient of a dietary supplement. S-23 as a SARM is on the WADA Prohibited List in category S1.2 (other anabolic agents) – a permanently prohibited substance, both in competition and out of competition. Marketing the product as an “oral muscle gainer”, “testosterone alternative” or “male contraception” is inconsistent with the Research Use Only framework.